Literature DB >> 12746230

Different molecular sites of action for the KATP channel inhibitors, PNU-99963 and PNU-37883A.

Yi Cui1, Andrew Tinker, Lucie H Clapp.   

Abstract

1. We investigated the mechanism of action of two novel nonsulphonylurea ATP-sensitive potassium channel (K(ATP)) inhibitors, PNU-99963 and PNU-37883A, on four types of cloned K(ATP) channels. 2. Whole-cell currents were recorded in a symmetrical potassium (140 mM) gradient in HEK-293 cells stably expressing Kir6.2/SUR1, Kir6.2/SUR2A, Kir6.2/SUR2B or Kir6.1/SUR2B. 3. PNU-99963 potently inhibited the four K(ATP) channel clones. The concentration at which half-maximum current was inhibited (IC(50)) was 66, 41, 43 and 11 nM for Kir6.2/SUR1, Kir6.2/SUR2A, Kir6.2/SUR2B and Kir6.1/SUR2B, respectively. In contrast, PNU-99963 up to a concentration of 3 microM had no significant effect on current generated in HEK-293 cells by transiently expressing Kir6.2Delta26, a C-terminal truncated pore-forming subunit of Kir6.2. 4. PNU-37883A inhibited four types of K(ATP) channels, but to different extents. Inhibition of the putative smooth muscle K(ATP) channel types, Kir6.2/SUR2B (IC(50); 15 microM) and Kir6.1/SUR2B (IC(50); 6 microM), was significantly greater than inhibition of either the pancreatic beta cell or cardiac K(ATP) channel clones. Moreover, PNU-37883A significantly inhibited currents generated by expressing Kir6.2Delta26 alone, with an IC(50) of 5 microM, which was significantly increased to 38 microM when Kir6.2Delta26 was expressed with SUR2B. 5. In conclusion, two structurally different nonsulphonylurea compounds, PNU-99963 and PNU-37883A, inhibit K(ATP) channels via different mechanisms, namely through the sulphonylurea receptor (SUR) and the pore-forming subunits, respectively, although SUR2B reduced the inhibitory effect of PNU-37883A. While PNU-99963 potently inhibits all the four cloned K(ATP) channels, PNU-37883A has a degree of selectivity towards both smooth muscle K(ATP) channels, but could not discriminate between them.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746230      PMCID: PMC1573826          DOI: 10.1038/sj.bjp.0705228

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

Review 1.  Sulfonylurea receptors: ABC transporters that regulate ATP-sensitive K(+) channels.

Authors:  J Bryan; L Aguilar-Bryan
Journal:  Biochim Biophys Acta       Date:  1999-12-06

Review 2.  New windows on the mechanism of action of K(ATP) channel openers.

Authors:  F M Ashcroft; F M Gribble
Journal:  Trends Pharmacol Sci       Date:  2000-11       Impact factor: 14.819

3.  The molecular composition of K(ATP) channels in human pulmonary artery smooth muscle cells and their modulation by growth.

Authors:  Yi Cui; Sandy Tran; Andrew Tinker; Lucie H Clapp
Journal:  Am J Respir Cell Mol Biol       Date:  2002-01       Impact factor: 6.914

4.  Nucleotide modulation of pinacidil stimulation of the cloned K(ATP) channel Kir6.2/SUR2A.

Authors:  F M Gribble; F Reimann; R Ashfield; F M Ashcroft
Journal:  Mol Pharmacol       Date:  2000-06       Impact factor: 4.436

5.  Assembly limits the pharmacological complexity of ATP-sensitive potassium channels.

Authors:  Jonathan P Giblin; Yi Cui; Lucie H Clapp; Andrew Tinker
Journal:  J Biol Chem       Date:  2002-02-01       Impact factor: 5.157

Review 6.  Adenosine 5'-triphosphate-sensitive potassium channels.

Authors:  F M Ashcroft
Journal:  Annu Rev Neurosci       Date:  1988       Impact factor: 12.449

7.  Pharmacological comparison of native mitochondrial K(ATP) channels with molecularly defined surface K(ATP) channels.

Authors:  Y Liu; G Ren; B O'Rourke; E Marbán; J Seharaseyon
Journal:  Mol Pharmacol       Date:  2001-02       Impact factor: 4.436

8.  Coexpression with the inward rectifier K(+) channel Kir6.1 increases the affinity of the vascular sulfonylurea receptor SUR2B for glibenclamide.

Authors:  U Russ; A Hambrock; F Artunc; C Löffler-Walz; Y Horio; Y Kurachi; U Quast
Journal:  Mol Pharmacol       Date:  1999-11       Impact factor: 4.436

9.  Pharmacological plasticity of cardiac ATP-sensitive potassium channels toward diazoxide revealed by ADP.

Authors:  N D'hahan; C Moreau; A L Prost; H Jacquet; A E Alekseev; A Terzic; M Vivaudou
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

10.  A mechanism for ATP-sensitive potassium channel diversity: Functional coassembly of two pore-forming subunits.

Authors:  Y Cui; J P Giblin; L H Clapp; A Tinker
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  6 in total

1.  Molecular analysis of the subtype-selective inhibition of cloned KATP channels by PNU-37883A.

Authors:  H Kovalev; J M Quayle; T Kamishima; D Lodwick
Journal:  Br J Pharmacol       Date:  2004-02-02       Impact factor: 8.739

2.  The pore-forming subunit of the K(ATP) channel is an important molecular target for LPS-induced vascular hyporeactivity in vitro.

Authors:  Alastair J O'Brien; Gita Thakur; James F Buckley; Mervyn Singer; Lucie H Clapp
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

3.  Rosiglitazone selectively inhibits K(ATP) channels by acting on the K(IR) 6 subunit.

Authors:  Lei Yu; Xin Jin; Ningren Cui; Yang Wu; Zhenda Shi; Daling Zhu; Chun Jiang
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 4.  Kir6.1 and SUR2B in Cantú syndrome.

Authors:  Conor McClenaghan; Colin G Nichols
Journal:  Am J Physiol Cell Physiol       Date:  2022-07-25       Impact factor: 5.282

5.  Mechanisms of U46619-induced contraction of rat pulmonary arteries in the presence and absence of the endothelium.

Authors:  C McKenzie; A MacDonald; A M Shaw
Journal:  Br J Pharmacol       Date:  2009-04-22       Impact factor: 8.739

6.  Changes of imidazoline receptors in spontaneously hypertensive rats.

Authors:  Guang-Yuan Mar; Ming-Ting Chou; Hsien-Hui Chung; Nien-Hua Chiu; Mei-Fen Chen; Juei-Tang Cheng
Journal:  Int J Exp Pathol       Date:  2012-11-24       Impact factor: 1.925

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.